Search
Denifanstat
go.drugbank.com/drugs/DB17576InvestigationalDenifanstat is an orally bioavailable fatty acid synthase (FASN) inhibitor. Due to its antineoplastic activities, it is being investigated for various cancers.
E1v1.11
go.drugbank.com/drugs/DB18363ExperimentalE1v1.11 is an antisense oligonucleotide targeting the _SMN2_ gene which is under investigation for the treatment of spinal muscular atrophy (SMA).[L48196]
KB3305
go.drugbank.com/drugs/DB06349ExperimentalKB3305 is an investigational liver selective antagonist for the glucocorticoid receptor, developed by Karo Bio for the treatment of Type 2 Diabetes.
Synonyms: (4R)-4-((3S,5R,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-DIHYDROXY-3-(2-(4-((8S,11R,13S,14S,17S)-17-HYDROXY-13-METHYL-3-OXO-17-PROP-1-YNYL-1,2,6,7,8,11,12,14,15,16-DECAHYDROCYCLOPENTA(A)PHENANTHREN-11-YL)-N-METHYL-ANILINOPrifinium
go.drugbank.com/drugs/DB13254ExperimentalPrifinium is an antimuscarinic agent with antispasmodic and antiemetic properties. It may be useful for the treatment of irritable bowel syndrome [A175027].
Calanolide A
go.drugbank.com/drugs/DB04886InvestigationalCalanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity. … A preliminary dosing study among HIV-infected individuals showed a significant antiviral effect compared with placebo.
Synonyms: Calanolide A, (+)-calanolide AATL1101
go.drugbank.com/drugs/DB05023ExperimentalATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis. … ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis.
Tofisopam
go.drugbank.com/drugs/DB08811InvestigationalTofisopam (marketed under brand names Emandaxin and Grandaxin) is a 2,3-benzodiazepine drug which is a benzodiazepine derivative.
Ecallantide
go.drugbank.com/drugs/DB05311ApprovedBy reversibly binding to plasma kallikrein, ecallantide displays a rapid on-rate and a slow off-rate that results in high affinity inhibition in the picomolar range [L1458]. … Ecallantide is a potent and selective human plasma kallikrein inhibitor that is indicated for the symptomatic treatment of hereditary angioedema.
Ulotaront
go.drugbank.com/drugs/DB15665InvestigationalSEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. … [L12891] An initial clinical study has shown this drug may be effective against both positive and negative symptoms of schizophrenia.
COVID-19 convalescent plasma
go.drugbank.com/drugs/DB15692Investigational[L14333] Although there are no formal clinical trial results for the safety or efficacy of COVID-19 convalescent plasma, early results from 5000 patients under the FDA expanded access program suggest … treatment is currently available through three main pathways: use in registered clinical trials, use through the expanded access COVID-19 protocol (21 CFR 312.305), and use for single patients through an